• Molecular NameVinblastine
  • SynonymNA
  • Weight810.989
  • Drugbank_IDDB00570
  • ACS_NO865-21-4
  • Show 3D model
  • LogP (experiment)3.7
  • LogP (predicted, AB/LogP v2.0)4.04
  • pka5.4, 7.4
  • LogD (pH=7, predicted)3.47
  • Solubility (experiment)Insoluble
  • LogS (predicted, ACD/Labs)(ph=7)-3.05
  • LogSw (predicted, AB/LogsW2.0)1.17
  • Sw (mg/ml) (predicted, ACD/Labs)0.12
  • No.of HBond Donors3
  • No.of HBond Acceptors13
  • No.of Rotatable Bonds10
  • TPSA154.1
  • StatusFDA approved
  • AdministrationExclusively intravenous
  • PharmacologyAn antimicrotubule drug used to treat certain kinds of cancer, including Hodgkin's lymphoma, non-small cell lung cancer, breast cancer, head and neck cancer, and testicular cancer.
  • Absorption_valueN/A
  • Absorption (description)Vinblastine sulfate in the dry state is irregularly and unpredictably absorbed from the gastrointestinal tract following oral administration. Absorption of the solution has not been studied. If vinblastine is swallowed, activated charcoal in a water slurry may be given by mouth along with a cathartic. The use of cholestyramine in this situation has not been reported.
  • Caco_2N/A
  • Bioavailability0.0
  • Protein binding99.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic (CYP3A4-mediated)
  • Half life20 h
  • ExcretionBiliary and renal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityOral, mouse: LD50 = 423 mg/kg; Oral, rat: LD50 = 305 mg/kg.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A